Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL784952 | 0.94 | CA2 (0.38) | CA2ALDH1A1POLBTYRSMN1; SMN2 | |
| SCHEMBL2741247 | 0.92 | ALDH1A1 (0.33) | CA2ALDH1A1POLBTYRSMN1; SMN2 | |
| SCHEMBL15504703 | 0.86 | ALDH1A1 (0.33) | CA2ALDH1A1POLBTYRSMN1; SMN2 | |
| SCHEMBL784967 | 0.85 | CA2 (0.36) | CA2ALDH1A1POLBTYRSMN1; SMN2 | |
| SCHEMBL8106600 | 0.85 | CA2 (0.36) | CA2ALDH1A1POLBTYRSMN1; SMN2 | |
| SCHEMBL11656526 | 0.83 | ALDH1A1 (0.32) | CA2ALDH1A1POLBTYRSMN1; SMN2 | |
| SCHEMBL11529852 | 0.83 | ALDH1A1 (0.32) | CA2ALDH1A1POLBTYRSMN1; SMN2 | |
| SCHEMBL9068216 | 0.82 | CA2 (0.35) | CA2ALDH1A1POLBTYRSMN1; SMN2 | |
| SCHEMBL7907472 | 0.79 | CA2 (0.36) | CA2ALDH1A1POLBTYRSMN1; SMN2 | |
| SCHEMBL20558662 | 0.77 | CA2 (0.35) | CA2ALDH1A1POLBTYRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541120-B2 | Phosphonium-based ionic drug conjugates | ANTHOS PARTNERS, LP (US) | 2023-01-03 | — | — | US | disclosed |
| US-20200353087-A1 | PHOSPHONIUM-BASED IONIC DRUG CONJUGATES | ANTHOS PARTNERS, LP | 2020-11-12 | — | — | US | disclosed |
| US-9523060-B2 | Lubricant oil compositions | POLNOX CORPORATION (US) | 2016-12-20 | — | — | US | disclosed |
| US-20150159109-A1 | Lubricant Oil Compositions | POLNOX CORPORATION | 2015-06-11 | — | — | US | disclosed |
| US-8927472-B2 | Lubricant oil compositions | POLNOX CORPORATION (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130130955-A1 | LUBRICANT OIL COMPOSITIONS | POLNOX CORPORATION (US) | 2013-05-23 | — | — | US | disclosed |
| US-20120004150-A1 | Lubricant Oil Compositions | POLNOX CORPORATION | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200353087-A1 | PHOSPHONIUM-BASED IONIC DRUG CONJUGATES | SLC8B1, PHOSPHO1, PBDC1 | CA2 533/4885ALDH1A1 4047/4885POLB 1236/4885 |
| US-11541120-B2 | Phosphonium-based ionic drug conjugates | SLC8B1, PHOSPHO1, PBDC1 | CA2 533/4885ALDH1A1 4047/4885POLB 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.